Literature DB >> 14557598

Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes.

Duncan A E Cochran1, Caroline A Evans, David Blinco, John Burthem, Freda K Stevenson, Simon J Gaskell, Anthony D Whetton.   

Abstract

Chronic lymphocytic leukemia (CLL) is a common hematopoietic malignant disease with variable outcome. CLL has been divided into distinct groups based on whether somatic hypermutation has occurred in the variable region of the immunoglobulin heavy-chain locus or alternatively if the cells express higher levels of the CD38 protein. We have analyzed the proteome of 12 cases of CLL (six mutated (M-CLL) and six unmutated (UM-CLL) immunoglobulin heavy-chain loci; seven CD38-negative and five CD38-positive) using two-dimensional electrophoresis and mass spectrometry. Statistical evaluation using principal component analysis indicated significant differences in patterns of protein expression between the cases with and without somatic mutation. Specific proteins indicated by principal component analysis as varying between the prognostic groups were characterized using mass spectrometry. The levels of F-actin-capping protein beta subunit, 14-3-3 beta protein, and laminin-binding protein precursor were significantly increased in M-CLL relative to UM-CLL. In addition, primary sequence data from tandem mass spectrometry showed that nucleophosmin was present as several protein spots in M-CLL but was not detected in UM-CLL samples, suggesting that several post-translationally modified forms of nucleophosmin vary between these two sample groups. No specific differences were found between CD38-positive and -negative patient samples using the same approach. The results presented show that proteomic analysis can complement other approaches in identifying proteins that may have potential value in the biological and diagnostic distinction between important clinical subtypes of CLL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14557598     DOI: 10.1074/mcp.M300055-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  6 in total

1.  Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents.

Authors:  David R Barnidge; Diane F Jelinek; David C Muddiman; Neil E Kay
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

2.  A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia.

Authors:  Aurore Perrot; Cédric Pionneau; Sophie Nadaud; Frédéric Davi; Véronique Leblond; Frédéric Jacob; Hélène Merle-Béral; Raoul Herbrecht; Marie-Christine Béné; John G Gribben; Seiamak Bahram; Laurent Vallat
Journal:  Blood       Date:  2011-05-20       Impact factor: 22.113

Review 3.  Post-genomics nanotechnology is gaining momentum: nanoproteomics and applications in life sciences.

Authors:  Firas H Kobeissy; Basri Gulbakan; Ali Alawieh; Pierre Karam; Zhiqun Zhang; Joy D Guingab-Cagmat; Stefania Mondello; Weihong Tan; John Anagli; Kevin Wang
Journal:  OMICS       Date:  2014-01-10

4.  Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.

Authors:  Harvey E Johnston; Matthew J Carter; Marta Larrayoz; James Clarke; Spiro D Garbis; David Oscier; Jonathan C Strefford; Andrew J Steele; Renata Walewska; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2018-01-24       Impact factor: 5.911

Review 5.  Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.

Authors:  Clive S Zent; Neil E Kay
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

6.  Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.

Authors:  Gina L Eagle; Jianguo Zhuang; Rosalind E Jenkins; Kathleen J Till; Puthen V Jithesh; Ke Lin; Gillian G Johnson; Melanie Oates; Kevin Park; Neil R Kitteringham; Andrew R Pettitt
Journal:  Mol Cell Proteomics       Date:  2015-02-02       Impact factor: 5.911

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.